Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives. - Wikidata - awgldk - TriplyDB

Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.

Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.

http://www.wikidata.org/entity/Q35450340

about

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors Heterogeneous distribution of alectinib in neuroblastoma xenografts revealed by matrix-assisted laser desorption ionization mass spectrometry imaging: a pilot study.

P2860

Q36237312-6BFA77B2-DC68-4187-A1D4-D9A7B280CFC2 Q48193794-AADD1E58-239B-4504-A7A7-96512611ED6C

P2860

Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.

http://www.wikidata.org/entity/Q35450340

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Quantitation of VEGFR2 (vascul ...... ethodologies and perspectives.

@ast

Quantitation of VEGFR2 (vascul ...... ethodologies and perspectives.

@en

type

label

Quantitation of VEGFR2 (vascul ...... ethodologies and perspectives.

@ast

Quantitation of VEGFR2 (vascul ...... ethodologies and perspectives.

@en

prefLabel

Quantitation of VEGFR2 (vascul ...... ethodologies and perspectives.

@ast

Quantitation of VEGFR2 (vascul ...... ethodologies and perspectives.

@en

P1433

Q35450340-04040771-BBAE-4E53-B529-381D88DD9973

P1476

Q35450340-B2422164-04B2-4573-8EEE-3B44A836491F

P2093

Q35450340-397E1A22-71B1-4792-A70B-479A48238781

Q35450340-4665785D-3E2C-432F-B965-D7CA32E68599

Q35450340-7FED6E72-0FB6-470B-BFD8-03333E43E8C1

Q35450340-BBBEBCA7-902D-48C6-BB20-07F134D1C7BE

P2860

Q35450340-029800F6-2BFA-45C5-8CA7-785CBD4BE1A6

Q35450340-09D8DD42-91ED-4CF4-A1AB-5DC5489C4856

Q35450340-0C7F015D-A105-4379-8011-633DC9C0EDAD

Q35450340-12EF3A5F-C694-4272-8992-2307294B77EA

Q35450340-16F3E09D-9A6F-41F8-8BD9-3FC64AA2C0B5

Q35450340-319064C8-ABDB-475C-87F9-14D5AC7E408E

Q35450340-325F5875-74E6-4A4A-BFA9-B6C7E54CFF85

Q35450340-389FF54F-B7E1-4CAB-A534-9D19BF31A986

Q35450340-3E5A14FB-D6B3-4285-B6F1-CBDD82B67447

Q35450340-4622B8BB-C5B2-4E5E-ABA4-658AC7D27589

P304

Q35450340-6A957080-5FFF-4F0B-818E-642D56E34BE4

P31

Q35450340-AB57A4B2-93EF-4AD4-BEDF-E7019F55EE16

P356

Q35450340-FA05DFEE-C10C-4B6E-A836-D598B77707EF

P433

Q35450340-3BCF3D7F-3F58-41F8-A631-6FDDC9A67183

P478

Q35450340-2AA104CB-BE10-47C1-97F0-E44D66AA8B49

P577

Q35450340-622CDBBE-1211-43CC-A772-060A2CF4A465

P698

Q35450340-3EA55358-B198-4CFB-BCBF-EB024EB8106D

P921

Q35450340-6AF16D80-8435-44C4-888F-76A84266822B

P356

P1433

Biomedical Chromatography

P1476

Quantitation of VEGFR2 (vascul ...... ethodologies and perspectives.

@en

P2093

Kuldeep Sharma

http://www.w3.org/2001/XMLSchema#string

N R Srinivas

http://www.w3.org/2001/XMLSchema#string

P S Suresh

http://www.w3.org/2001/XMLSchema#string

Ramesh Mullangi

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting receptor tyrosine kinases in gastric cancer

Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry.

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours.

Quantification of sunitinib in mouse plasma, brain tumor and normal brain using liquid chromatography-electrospray ionization-tandem mass spectrometry and pharmacokinetic application.

Highly sensitive method for the determination of a novel triple kinase inhibitor with anti-cancer activity, JI-101, in rat plasma by liquid chromatography-electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study.

Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy.

Highly sensitive method for the determination of JI-101, a multi-kinase inhibitor in human plasma and urine by LC-MS/MS-ESI: method validation and application to a clinical pharmacokinetic study.

A strategy for extending the applicability of a validated plasma calibration curve to quantitative measurements in multiple tissue homogenate samples: a case study from a rat tissue distribution study of JI-101, a triple kinase inhibitor.

Quantitation of unbound sunitinib and its metabolite N-desethyl sunitinib (SU12662) in human plasma by equilibrium dialysis and liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study.

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry

P304

803-834

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BMC.3370

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25424874

http://www.w3.org/2001/XMLSchema#string

P921